HX044
Phase 2Small molecule
HX044 is one of 14 small molecule programs targeting Solid Tumor Malignancies. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
19 competitors in Solid Tumor Malignancies
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Lumakras
AmgenPhase 2
Verzenio
Eli LillyPhase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Herceptin
OOrganon and Co
Phase 2
Taxotere
AAvyxa
Phase 2
Faslodex
FFresenius Kabi USA, LLC
Phase 2
Fludara
SanofiPhase 1
GV20-0251
GGV20 Therapeutics
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HX044. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details